Interesting article at Science Daily.
Here, they are comparing the use of stem cells from the patient (nonallogeneic, or autologous) or from a donor (allogeneic). ESC are effectively always allogeneic.
The findings indicate that allogeneic treatments only benefit medium and high risk patients.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment